Salute e Benessere
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
COPENHAGEN, Denmark, September 6, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company's shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such.
The transactions concern the sale of shares following a recent exercise of warrants granted to members of the executive management as part of incentive programs launched in 2019 and 2020. The net gain from these transactions is subject to taxation, and thus a significant part of the sale is executed to off-set tax obligations. After these transactions, the net holdings of shares in Bavarian Nordic for members of the executive management has increased.
About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccine company with a mission to protect and save lives through innovative vaccines. We are a global leader in smallpox and mpox vaccines, supplied to governments to enhance public health preparedness and have a strong portfolio of vaccines for travelers and endemic diseases. For more information visit
www.bavarian-nordic.com .
Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations,
rss@bavarian-nordic.com , Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors,
graham@paddockcircle.com , Tel: +1 781 686 9600
Company Announcement no. 29 / 2024
Attachment
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti